verapamil has been researched along with Adenocarcinoma Of Kidney in 9 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Toxicities included hypotension, asymptomatic bradycardia, and mild atrioventricular conduction delays, although one patient had dexverapamil discontinued for grade IV congestive heart failure." | 5.08 | Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. ( Cordon-Cardo, C; Fischer, P; Lianes, P; Lyn, P; Motzer, RJ; Ngo, RL; O'Brien, JP, 1995) |
| "Cells from 22 renal cell carcinomas (RCC) were established in culture." | 1.29 | Verapamil enhances doxorubicin activity in cultured human renal carcinoma cells. ( Collins, CM; Hall, P; Lai, T; Morgan, AP; Smith, PJ; Stonebridge, BR; Symes, MO, 1993) |
| "Human renal adenocarcinomas do not adequately respond to cancer chemotherapy." | 1.29 | [Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma]. ( Deguchi, T; Ehara, H; Kawada, Y; Kawamoto, S; Nezasa, S; Okano, M; Tamaki, M; Yamada, S, 1996) |
| "Multidrug resistance in human renal cell carcinoma is mainly caused by expression of the MDR1 gene and is characterized by a broad spectrum cross resistance to many natural product chemotherapeutic agents." | 1.28 | New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. ( Aiken, PM; Gottesman, MM; Merlino, GT; Mickisch, GH; Pastan, I, 1991) |
| "Human renal cell carcinomas show a high degree of intrinsic multidrug resistance." | 1.28 | Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. ( Alken, PM; Forster, S; Koessig, J; Mickisch, GH; Roehrich, K; Tschada, RK, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Strobbe, G | 1 |
| Pannier, D | 1 |
| Sakji, I | 1 |
| Villain, A | 1 |
| Feutry, F | 1 |
| Marliot, G | 1 |
| Motzer, RJ | 1 |
| Lyn, P | 1 |
| Fischer, P | 1 |
| Lianes, P | 1 |
| Ngo, RL | 1 |
| Cordon-Cardo, C | 1 |
| O'Brien, JP | 1 |
| Lai, T | 1 |
| Collins, CM | 1 |
| Hall, P | 1 |
| Morgan, AP | 1 |
| Smith, PJ | 1 |
| Stonebridge, BR | 1 |
| Symes, MO | 1 |
| Mickisch, GH | 3 |
| Noordzij, MA | 1 |
| vd Gaast, A | 1 |
| Gebreamlack, P | 1 |
| Köhrmann, KU | 1 |
| Mogler-Drautz, E | 1 |
| Kupper, H | 1 |
| Schröder, FH | 1 |
| Okano, M | 1 |
| Kawamoto, S | 1 |
| Nezasa, S | 1 |
| Tamaki, M | 1 |
| Ehara, H | 1 |
| Yamada, S | 1 |
| Deguchi, T | 1 |
| Kawada, Y | 1 |
| Yu, DS | 1 |
| Sun, GH | 1 |
| Ma, CP | 1 |
| Chang, SY | 1 |
| Merlino, GT | 1 |
| Aiken, PM | 1 |
| Gottesman, MM | 1 |
| Pastan, I | 1 |
| Roehrich, K | 1 |
| Koessig, J | 1 |
| Forster, S | 1 |
| Tschada, RK | 1 |
| Alken, PM | 1 |
| Watanabe, Y | 1 |
2 trials available for verapamil and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bradycardia; Carcinoma, Renal | 1995 |
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
7 other studies available for verapamil and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: A case report.
Topics: Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Everolimus; Female; Humans; Immunosuppres | 2020 |
Verapamil enhances doxorubicin activity in cultured human renal carcinoma cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Carrier Proteins; Do | 1993 |
[Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Bloc | 1996 |
Verapamil modulation of multidrug resistance in renal cell carcinoma.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Doxorubicin; Drug Re | 2000 |
New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Daunorubici | 1991 |
Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.
Topics: Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; But | 1990 |
[Enhancement of cytotoxicity of anticancer drugs by verapamil--effects on established human renal tumor cell line].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitum | 1988 |